Acumen Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Acumen is a clinical-stage biopharmaceutical company focused on ACU193, an antibody designed to target soluble amyloid-beta oligomers in Alzheimer’s disease. It had no product revenue and remains loss-making.
Financial performance and position
Amounts below are in millions of dollars unless stated otherwise. Interim financial statements are unaudited.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $9.1 | $7.3 | $17.8 | $13.3 |
| General and administrative expense | $4.3 | $3.1 | $8.8 | $6.3 |
| Total operating expenses | $13.5 | $10.4 | $26.6 | $19.6 |
| Net loss | $11.6 | $10.2 | $22.9 | $19.3 |
| Net loss per share, basic and diluted | $0.28 | $0.25 | $0.56 | $0.48 |
| Operating cash used | Not stated by quarter | Not stated by quarter | $21.8 | $14.8 |
- Q2 operating expenses rose 29% year over year; six-month expenses rose 36%. Higher clinical-trial, personnel, consulting, manufacturing and other development costs drove the increases.
- Net loss increased 14% for Q2 and 19% for the first half. Net interest income rose to $1.9 million in Q2 and $3.7 million for the first half, principally due to higher interest rates.
- At June 30, cash and cash equivalents were $77.2 million and marketable securities were $94.9 million, totaling $172.2 million. Working capital was $141.0 million. Total assets were $177.4 million; total liabilities were $8.5 million, with no debt reported.
- Six-month investing cash outflow was $30.9 million, primarily reflecting net purchases of marketable securities. Cash and cash equivalents declined $52.9 million to $77.2 million during the first half.
- No meaningful revenue-based margin is available because the company had no product sales. The filing does not provide a clear quarterly cash-flow figure.
Business developments, outlook and risks
- In July 2023, Acumen announced topline Phase 1 INTERCEPT-AD results. The trial enrolled 65 participants; the topline findings described results in 60 participants. The company reported that ACU193 met primary and secondary objectives, with dose-related target engagement and reductions in amyloid plaque measures at higher doses. The study was small and short, and exploratory cognitive and cerebral blood-flow measures showed no discernible acute effects.
- Reported safety findings included ARIA-E in 10.4% of participants, including one symptomatic case (2.1%); three serious adverse events were deemed unrelated or unlikely related to ACU193. Full results were expected at a future medical congress and in a peer-reviewed publication.
- Management expected to meet with the FDA in Q4 2023 to discuss next steps and the feasibility and timing of a Phase 2/3 study. The company planned to initiate the Phase 2 portion in the first half of 2024 and was assessing possible subcutaneous administration. These are forward-looking plans, not assured outcomes.
- On July 21, 2023, after quarter-end, the company sold 16,774,193 shares at $7.75 per share for estimated net proceeds of $122.2 million. Underwriters had an option, exercisable through August 17, 2023, to buy up to 2,516,128 additional shares. The offering increases liquidity but dilutes existing shareholders.
- Including the offering proceeds, management estimated that available cash and securities would fund operating and capital needs into the second half of 2026. This estimate depends on assumptions and could change with spending, trial plans or capital needs. Acumen expects expenses and losses to rise as development advances and may need additional financing or partners; financing could be unavailable or dilutive, and programs could be delayed, reduced or terminated.
- Other disclosed considerations include interest-rate and market risks affecting investments, reliance on third-party research, clinical and manufacturing providers, and Lonza license payments and potential low-single-digit royalties on future ACU193 net sales. The company reported no material legal proceedings and no material changes to its previously disclosed risk factors.
Most important facts for investors to verify
- Review the complete INTERCEPT-AD data, including the 65 enrolled versus 60-participant topline analysis, safety results, durability, and any subsequent FDA feedback or trial plans.
- Confirm the final proceeds and whether underwriters exercised their additional-share option; assess the resulting dilution and updated share count.
- Track operating cash burn and clinical spending against management’s stated funding runway into the second half of 2026.
- Monitor whether planned Phase 2 development proceeds on schedule and whether ACU193 demonstrates clinical benefit beyond the Phase 1 findings.